Zobrazeno 1 - 10
of 10
pro vyhledávání: '"N. KurtYilmaz"'
Autor:
Celia A. Schiffer, Shahid N. Khan, John D. Persons, Janet L. Paulsen, Rieko Ishima, N. KurtYilmaz, Michel Guerrero
Publikováno v:
Biochemistry. 57:1652-1662
In the era of state-of-the-art inhibitor design and high-resolution structural studies, detection of significant but small protein structural differences in the inhibitor-bound forms is critical to further developing the inhibitor. Here, we probed di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa83122dc8afd1c5fa334e3d39ccfd8c
https://doi.org/10.1021/acs.biochem.7b01238
https://doi.org/10.1021/acs.biochem.7b01238
Autor:
N. KurtYilmaz, Troy W. Whitfield, Sook Kyung Lee, Debra A. Ragland, Ronald Swanstrom, Celia A. Schiffer, Konstantin B. Zeldovich
Publikováno v:
Journal of Chemical Theory and Computation. 13:5671-5682
HIV-1 protease is responsible for the cleavage of 12 non-homologous sites within the Gag and Gag-Pro-Pol polyproteins in the viral genome. Under the selective pressure of protease inhibition, the virus evolves mutations within (primary) and outside o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fe62ac2feb2a58daf30e450ff4e846
https://doi.org/10.1021/acs.jctc.7b00601
https://doi.org/10.1021/acs.jctc.7b00601
Autor:
N. KurtYilmaz, Jacqueto Zephyr, Celia A. Schiffer, Christos J. Petropoulos, Ashley N. Matthew, Caitlin. J. Hill, Akbar Ali, Muhammad Jahangir, Wei Huang, Alicia Newton
Publikováno v:
Journal of Medicinal Chemistry. 60:5699-5716
A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26fa2c4021d20b153d5d21215bc589a0
https://doi.org/10.1021/acs.jmedchem.7b00426
https://doi.org/10.1021/acs.jmedchem.7b00426
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kelly M. Thayer, Jennifer P. Wang, Konstantin B. Zeldovich, Jeffrey D. Jensen, N. KurtYilmaz, Kristina L. Prachanronarong, L. Safak Yilmaz, Robert W. Finberg, Ayşegül Özen, Celia A. Schiffer, Daniel N. Bolon, Timothy F. Kowalik
Publikováno v:
Journal of Chemical Theory and Computation. 12:6098-6108
Neuraminidase (NA) inhibitors are used for the prevention and treatment of influenza A virus infections. Two subtypes of NA, N1 and N2, predominate in viruses that infect humans, but differential patterns of drug resistance have emerged in each subty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbbd25cea604abd1bf18a85a5dee177
https://doi.org/10.1021/acs.jctc.6b00703
https://doi.org/10.1021/acs.jctc.6b00703
Autor:
Jeffrey D. Jensen, Ping Liu, Wayne A. Marasco, Konstantin B. Zeldovich, Robert W. Finberg, Aneth S. Canale, N. KurtYilmaz, Nicholas Renzette, Celia A. Schiffer, Shurong Hou, Quan Zhu, Yu Ping Poh, Daniel N. Bolon, Jennifer P. Wang, Kristina L. Prachanronarong, Timothy F. Kowalik, Thomas Han, Mohan Somasundaran
Publikováno v:
Journal of Virology
Influenza A virus (IAV), a major cause of human morbidity and mortality, continuously evolves in response to selective pressures. Stem-directed, broadly neutralizing antibodies (sBnAbs) targeting the influenza virus hemagglutinin (HA) are a promising
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e291fcb0e44d2ffbdd379daf0aef5cf0
https://europepmc.org/articles/PMC6321927/
https://europepmc.org/articles/PMC6321927/
Autor:
Celia A. Schiffer, Hong Cao, Ellen A. Nalivaika, Debra A. Ragland, Yufeng Cai, N. KurtYilmaz, Rajintha M. Bandaranayake, Kristina L. Prachanronarong, Madhavi N. L. Nalam
Publikováno v:
Journal of the American Chemical Society
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in the treatment of HIV infection and AIDS. Darunavir (DRV) is the most potent of these inhibitors, soliciting drug resistance only when a complex combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5564e1b0c4be78e415d21eb3f51e1a84
https://doi.org/10.1021/ja504096m
https://doi.org/10.1021/ja504096m
Publikováno v:
Journal of Virology. 88:7145-7154
Resistance to various human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) challenges the effectiveness of therapies in treating HIV-1-infected individuals and AIDS patients. The virus accumulates mutations within the protease (PR) t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03eb525063300940cbcc0459024cf270
https://doi.org/10.1128/jvi.00266-14
https://doi.org/10.1128/jvi.00266-14
Autor:
Christos J. Petropoulos, N. KurtYilmaz, Florian Leidner, Wei Huang, Ashley N. Matthew, Celia A. Schiffer, Akbar Ali, Alicia Newton
Publikováno v:
Structure. 26:1360-1372.e5
Despite significant progress in hepatitis C virus (HCV) protease inhibitor (PI) drug design, resistance remains a problem causing treatment failure. Double-substitution variants, notably Y56H/D168A, have emerged in patients who fail therapy with a PI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0549f4777fa03efdfb9d1b829bdada
https://doi.org/10.1016/j.str.2018.07.004
https://doi.org/10.1016/j.str.2018.07.004
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.